Literature DB >> 26573750

A 63-year-old man with chronic spontaneous urticaria.

Gordon L Sussman1, Jacques Hebert2, F Estelle R Simons2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26573750      PMCID： PMC4771538          DOI： 10.1503/cmaj.150154

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  18 in total

Review 1.  Histamine and H1-antihistamines: celebrating a century of progress.

Authors:  F Estelle R Simons; Keith J Simons
Journal:  J Allergy Clin Immunol       Date:  2011-10-27       Impact factor: 10.793

2.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Authors:  Marcus Maurer; Karin Rosén; Hsin-Ju Hsieh; Sarbjit Saini; Clive Grattan; Ana Gimenéz-Arnau; Sunil Agarwal; Ramona Doyle; Janice Canvin; Allen Kaplan; Thomas Casale
Journal:  N Engl J Med       Date:  2013-02-24       Impact factor: 91.245

Review 3.  Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use.

Authors:  David A Khan
Journal:  J Allergy Clin Immunol Pract       Date:  2013-08-02

4.  Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: case series.

Authors:  Elena Netchiporouk; Christopher H Nguyen; Thusanth Thuraisingham; Fatemeh Jafarian; Marcus Maurer; Moshe Ben-Shoshan
Journal:  Pediatr Allergy Immunol       Date:  2015-06-14       Impact factor: 6.377

5.  Chronic idiopathic urticaria (CIU) is no longer idiopathic: time for an update.

Authors:  M Maurer; C Bindslev-Jensen; A Gimenez-Arnau; K Godse; C E M Grattan; M Hide; A P Kaplan; M Makris; F E R Simons; Z Zhao; T Zuberbier; M K Church
Journal:  Br J Dermatol       Date:  2013-02       Impact factor: 9.302

Review 6.  Second-generation H1-antihistamines in chronic urticaria: an evidence-based review.

Authors:  Eric R Kavosh; David A Khan
Journal:  Am J Clin Dermatol       Date:  2011-12-01       Impact factor: 7.403

7.  The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.

Authors:  T Zuberbier; W Aberer; R Asero; C Bindslev-Jensen; Z Brzoza; G W Canonica; M K Church; L F Ensina; A Giménez-Arnau; K Godse; M Gonçalo; C Grattan; J Hebert; M Hide; A Kaplan; A Kapp; A H Abdul Latiff; P Mathelier-Fusade; M Metz; A Nast; S S Saini; M Sánchez-Borges; P Schmid-Grendelmeier; F E R Simons; P Staubach; G Sussman; E Toubi; G A Vena; B Wedi; X J Zhu; M Maurer
Journal:  Allergy       Date:  2014-04-30       Impact factor: 13.146

8.  Real-life experiences with omalizumab for the treatment of chronic urticaria.

Authors:  Gordon Sussman; Jacques Hébert; Carly Barron; Jia Bian; Rose-Marie Caron-Guay; Stéphanie Laflamme; Simon Stern
Journal:  Ann Allergy Asthma Immunol       Date:  2013-12-28       Impact factor: 6.347

9.  How to assess disease activity in patients with chronic urticaria?

Authors:  A Młynek; A Zalewska-Janowska; P Martus; P Staubach; T Zuberbier; M Maurer
Journal:  Allergy       Date:  2008-06       Impact factor: 13.146

10.  Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.

Authors:  Allen Kaplan; Dennis Ledford; Mark Ashby; Janice Canvin; James L Zazzali; Edward Conner; Joachim Veith; Nikhil Kamath; Petra Staubach; Thilo Jakob; Robert G Stirling; Piotr Kuna; William Berger; Marcus Maurer; Karin Rosén
Journal:  J Allergy Clin Immunol       Date:  2013-07       Impact factor: 10.793
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.